orchard
therapeutics
receives
positive
chmp
opinion
treatment
metachromatic
leukodystrophy
mld
first
therapy
recommended
full
marketing
authorization
eu
eligible
patients
confirmed
diagnosis
late
infantile
early
juvenile
mld
variants
treatment
libmeldy
shown
preserve
cognitive
motor
function
patients
libmeldy
backed
data
across
patients
years
demonstrating
potential
durability
hsc
gene
therapy
boston
london
globe
newswire
orchard
therapeutics
nasdaq
ortx
global
gene
therapy
leader
today
announced
committee
medicinal
products
human
use
chmp
european
medicines
agency
ema
adopted
positive
opinion
recommending
full
standard
marketing
authorization
libmeldy
cryopreserved
autologous
cells
encoding
arsa
gene
investigational
gene
therapy
treatment
metachromatic
leukodystrophy
mld
characterized
biallelic
mutations
arsa
gene
leading
reduction
arsa
enzymatic
activity
children
late
infantile
early
juvenile
forms
without
clinical
manifestations
disease
ii
early
juvenile
form
early
clinical
manifestations
disease
still
ability
walk
independently
onset
cognitive
decline
chmp
positive
opinion
reviewed
european
commission
ec
authority
grant
marketing
authorization
libmeldy
european
union
eu
final
decision
ec
libmeldy
anticipated
end
approved
libmeldy
would
first
commercial
therapy
first
gene
therapy
eligible
patients
mld
mld
rare
severe
genetic
condition
caused
mutations
arsa
gene
lead
neurological
damage
developmental
regression
severe
common
forms
young
children
rapidly
lose
ability
walk
talk
interact
world
around
majority
patients
pass
away
childhood
palliative
care
often
option
today
positive
chmp
opinion
marketing
authorization
libmeldy
remarkable
achievement
share
mld
community
brings
us
closer
delivering
potentially
transformative
therapy
eligible
children
suffering
devastating
disease
said
bobby
gaspar
chief
executive
officer
orchard
therapeutics
data
libmeldy
clinical
program
demonstrated
potential
positive
effects
cognitive
development
maintenance
motor
function
translating
individual
preservation
motor
milestones
ability
sit
stand
walk
without
support
well
attainment
cognitive
skills
like
social
interactions
school
attendance
ages
untreated
patients
show
severe
motor
cognitive
libmeldy
designed
gene
therapy
developed
partnership
san
institute
gene
therapy
milan
italy
patient
hematopoietic
stem
cells
hscs
selected
functional
copies
arsa
gene
inserted
genome
hscs
using
lentiviral
vector
genetically
modified
cells
infused
back
patient
ability
hscs
migrate
across
barrier
brain
engraft
express
functional
enzyme
potential
persistently
correct
underlying
genetic
condition
single
treatment
important
milestone
toward
making
availability
hsc
gene
therapy
reality
patients
also
extremely
rewarding
team
worked
relentlessly
along
journey
move
seminal
proof
principle
studies
first
testing
therapy
said
director
luigi
naldini
robust
durable
clinical
benefits
observed
mld
patients
received
hsc
gene
therapy
compelling
especially
compared
natural
history
disease
results
also
illustrate
view
hsc
gene
therapy
approach
potential
deliver
transformative
effects
storage
diseases
well
especially
cells
designed
overexpress
functional
enzyme
provide
enhanced
supply
affected
parent
watching
child
start
seemingly
normal
developmental
path
suddenly
rapidly
lose
abilities
agony
even
acute
knowing
approved
therapies
currently
exist
mld
said
georgina
morton
chair
archangel
mld
trust
today
decision
advance
libmeldy
final
ec
approval
stage
represents
huge
step
forward
parents
young
children
us
mld
extremely
appreciative
ema
expedited
thorough
review
libmeldy
marketing
authorization
application
considering
severity
mld
coupled
limited
treatment
options
available
today
young
patients
said
anne
dupraz
chief
regulatory
officer
orchard
therapeutics
agency
collaboration
assessment
testament
broader
public
health
commitment
ensure
timely
evaluation
new
medicines
diseases
pressing
unmet
need
data
supporting
clinical
profile
libmeldy
positive
chmp
opinion
supported
clinical
studies
libmeldy
symptomatic
mld
patients
mld
encompasses
disease
variants
traditionally
referred
late
infantile
li
early
juvenile
ej
clinical
efficacy
based
integrated
analysis
results
patients
mld
treated
libmeldy
prepared
fresh
formulation
patients
treated
registrational
study
median
years
patients
treated
expanded
access
programs
median
years
patients
diagnosis
li
mld
diagnosis
ej
mld
time
treatment
patients
deemed
deemed
clinical
safety
evaluated
patients
mld
patients
integrated
efficacy
analysis
patients
treated
cryopreserved
formulation
libmeldy
endpoints
endpoints
integrated
efficacy
analysis
gross
motor
function
measure
gmfm
total
score
arsa
activity
evaluated
years
results
analysis
indicate
intravenous
administration
libmeldy
effective
modifying
disease
course
mld
patients
li
ej
patients
treated
libmeldy
experienced
significantly
less
deterioration
motor
function
years
years
measured
gmfm
total
score
compared
age
disease
untreated
patients
mean
difference
treated
li
patients
untreated
li
patients
year
year
similarly
mean
difference
treated
ej
patients
untreated
ej
patients
year
year
although
statistically
significant
clear
difference
gmfm
total
score
also
noted
treated
ej
patients
untreated
ej
patients
year
year
statistically
significant
increase
arsa
activity
peripheral
blood
mononuclear
cells
observed
years
compared
patients
increase
p
patients
increase
time
integrated
data
analysis
treated
li
patients
alive
years
treated
ej
patients
alive
years
mortality
reported
patients
treated
libmeldy
key
secondary
endpoints
ej
patients
treated
libmeldy
meaningful
effects
motor
development
demonstrated
patients
treated
entering
rapidly
progressive
phase
disease
gross
motor
function
classification
gmfc
years
onset
estimated
treated
ej
mld
patients
survived
maintained
locomotion
ability
sit
without
support
compared
untreated
ej
mld
patients
representing
delay
disease
progression
following
treatment
libmeldy
secondary
efficacy
endpoint
measured
cognitive
language
abilities
quantified
intelligence
quotient
development
quotient
iq
dq
found
treated
li
subgroup
assessed
patients
fairly
constant
iq
dq
within
normal
range
iq
dq
score
sd
throughout
patients
remained
threshold
severe
mental
disability
iq
dq
chronological
ages
untreated
comparator
li
patients
showed
evidence
severe
cognitive
impairment
iq
dq
close
surviving
ej
patients
patients
patients
showed
normal
iq
dq
throughout
contrast
untreated
ej
patients
showed
evidence
severe
cognitive
impairment
clinical
safety
safety
data
indicate
libmeldy
generally
common
adverse
reaction
attributed
treatment
libmeldy
occurrence
antibodies
aaa
reported
patients
antibody
titers
patients
generally
low
negative
effects
observed
arsa
activity
peripheral
blood
bone
marrow
cellular
subpopulations
arsa
activity
within
cerebrospinal
fluid
treatment
libmeldy
preceded
medical
interventions
namely
bone
marrow
harvest
peripheral
blood
mobilization
apheresis
followed
myeloablative
conditioning
carry
risks
clinical
studies
safety
profiles
interventions
consistent
known
safety
tolerability
mld
investigational
libmeldy
metachromatic
leukodystrophy
mld
rare
inherited
disease
body
metabolic
system
occurring
approximately
one
every
live
births
mld
caused
mutation
arsa
gene
results
accumulation
sulfatides
brain
areas
body
including
liver
gallbladder
kidneys
spleen
time
nervous
system
damaged
leading
neurological
problems
motor
behavioral
cognitive
regression
severe
spasticity
seizures
patients
mld
gradually
lose
ability
move
talk
swallow
eat
see
currently
approved
treatments
mld
late
infantile
form
mortality
years
onset
estimated
years
juvenile
libmeldy
autologous
cell
enriched
population
contains
hematopoietic
stem
progenitor
cells
hspc
transduced
ex
vivo
using
lentiviral
vector
encoding
human
arsa
gene
formerly
studied
treatment
mld
certain
patients
libmeldy
acquired
gsk
april
originated
pioneering
collaboration
gsk
hospital
san
raffaele
fondazione
telethon
acting
joint
san
institute
gene
therapy
milan
initiated
orchard
orchard
therapeutics
global
gene
therapy
leader
dedicated
transforming
lives
people
affected
rare
diseases
development
innovative
potentially
curative
gene
therapies
ex
vivo
autologous
gene
therapy
approach
harnesses
power
genetically
modified
blood
stem
cells
seeks
correct
underlying
cause
disease
single
administration
orchard
acquired
gsk
rare
disease
gene
therapy
portfolio
originated
pioneering
collaboration
gsk
san
raffaele
telethon
institute
gene
therapy
milan
italy
orchard
one
deepest
advanced
gene
therapy
product
candidate
pipelines
industry
spanning
multiple
therapeutic
areas
disease
burden
children
families
caregivers
immense
current
treatment
options
limited
exist
orchard
global
headquarters
london
headquarters
boston
information
please
visit
follow
us
twitter
linkedin
availability
information
orchard
investors
others
note
orchard
communicates
investors
public
using
company
website
investor
relations
website
social
media
twitter
linkedin
including
limited
investor
presentations
investor
fact
sheets
securities
exchange
commission
filings
press
releases
public
conference
calls
webcasts
information
orchard
posts
channels
websites
could
deemed
material
information
result
orchard
encourages
investors
media
others
interested
orchard
review
information
posted
channels
including
investor
relations
website
regular
basis
list
channels
may
updated
time
time
orchard
investor
relations
website
may
include
additional
social
media
channels
contents
orchard
website
channels
website
may
accessed
website
channels
shall
deemed
incorporated
reference
filing
securities
act
statements
press
release
contains
certain
statements
orchard
strategy
future
plans
prospects
made
pursuant
safe
harbor
provisions
private
securities
litigation
reform
act
statements
may
identified
words
anticipates
believes
expects
plans
intends
projects
future
similar
expressions
intended
identify
statements
statements
include
express
implied
statements
relating
among
things
orchard
business
strategy
goals
including
plans
expectations
regulatory
approval
commercialization
libmeldy
therapeutic
potential
libmeldy
including
potential
implications
clinical
data
eligible
patients
statements
neither
promises
guarantees
subject
variety
risks
uncertainties
many
beyond
orchard
control
could
cause
actual
results
differ
materially
contemplated
statements
particular
risks
uncertainties
include
without
limitation
risk
marketing
authorization
application
submitted
libmeldy
may
approved
european
commission
expected
risk
prior
results
signals
safety
activity
durability
effect
observed
clinical
trials
libmeldy
continue
repeated
ongoing
planned
clinical
trials
libmeldy
insufficient
support
regulatory
submissions
marketing
approval
us
eu
adverse
safety
findings
may
discovered
inability
risk
delays
orchard
ability
commercialize
libmeldy
approved
including
risk
may
secure
adequate
pricing
reimbursement
support
continued
development
commercialization
libmeldy
severity
impact
pandemic
orchard
business
including
clinical
development
supply
chain
commercial
programs
given
uncertainties
reader
advised
place
undue
reliance
statements
risks
uncertainties
faced
orchard
include
identified
heading
risk
factors
orchard
quarterly
report
form
quarter
ended
june
filed
securities
exchange
commission
sec
well
subsequent
filings
reports
filed
sec
statements
contained
press
release
reflect
orchard
views
date
hereof
orchard
assume
specifically
disclaims
obligation
publicly
update
revise
statements
whether
result
new
information
future
events
otherwise
except
may
required
law
contacts
investors
renee
leck
director
investor
relations
media
christine
harrison
vice
president
corporate
affairs
media
mahmood
et
al
metachromatic
leukodystrophy
case
triplets
late
infantile
variant
systematic
review
literature
journal
child
neurology
doi
http
